The Procter & Gamble Company
—- Market cap
- $331.56B
- Debt
- +$34.14B
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 91% equity / 9% debt
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: PG stock price at discount vs LLY $142.64 current versus $324.28 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LLY's multiple
Implied fair value · at PG's multiple
Snapshot Sep 9, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 91% equity / 9% debt
Capital structure 96% equity / 4% debt · EV / Revenue 16.78x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
The Procter & Gamble Company · implied price per share
Bear
$81.64
Base
$98.63
Bull
$122.06
ELI LILLY AND COMPANY · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
COLGATE PALMOLIVE CO
PG vs CL
KIMBERLY CLARK CORP
PG vs KMB
CHURCH & DWIGHT CO INC /DE/
PG vs CHD
CLOROX CO /DE/
PG vs CLX
Johnson & Johnson
PG vs JNJ
Pfizer Inc.
PG vs PFE
Merck & Co., Inc.
PG vs MRK
AbbVie Inc.
PG vs ABBV
Amgen Inc.
PG vs AMGN
Bristol-Myers Squibb Company
PG vs BMY
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe PG's flat growth and mature margins should continue to justify only a mid-20s P/E rather than a re-rating toward LLY-like multiples, then avoid chasing LLY-implied upside because PG already sits above its DCF range and near the top of its historical band.
PG's current price of $144.49 is far below LLY-implied value of $325.88, but that LLY comparison is distorted because LLY trades on a much higher growth and profitability profile. Relative to PG's own valuation anchors, the stock sits above the DCF range and within the historical band, so LLY-based upside is not the most decision-useful signal here.
Supporting Metrics